Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors von Lito, Piro, Saborowski, Anna, Yue, Jingyin, Solomon, Martha, Joseph, Eric, Gadal, Sunyana, Saborowski, Michael, Kastenhuber, Edward, Fellmann, Christof, Ohara, Kazuhiro, Morikami, Kenji, Miura, Takaaki, Lukacs, Christine, Ishii, Nobuya, Lowe, Scott, Rosen, Neal

Volltext

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant von Sakamoto, Hiroshi, Tsukaguchi, Toshiyuki, Hiroshima, Sayuri, Kodama, Tatsushi, Kobayashi, Takamitsu, Fukami, Takaaki A., Oikawa, Nobuhiro, Tsukuda, Takuo, Ishii, Nobuya, Aoki, Yuko

Volltext

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1 von Nakanishi, Yoshito, Akiyama, Nukinori, Tsukaguchi, Toshiyuki, Fujii, Toshihiko, Satoh, Yasuko, Ishii, Nobuya, Aoki, Masahiro

Volltext

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor‐4 von Kashima, Kenji, Watanabe, Miho, Sato, Yasuko, Hata, Junichi, Ishii, Nobuya, Aoki, Yuko

Volltext

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells von OKAMOTO, Aikou, NIKAIDO, Takashi, KAWAGUCHI, Rie, ISONISHI, Seiji, TANAKA, Tadao, URASHIMA, Mitsuyoshi, OCHIAI, Kazunori, TAKAKURA, Satoshi, SAITO, Misato, AOKI, Yuko, ISHII, Nobuya, YANAIHARA, Nozomu, YAMADA, Kyosuke, TAKIKAWA, Osamu

Volltext

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor von Nakanishi, Yoshito, Mizuno, Hideaki, Sase, Hitoshi, Fujii, Toshihiko, Sakata, Kiyoaki, Akiyama, Nukinori, Aoki, Yuko, Aoki, Masahiro, Ishii, Nobuya

Volltext

Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor‐D von Kashima, Kenji, Watanabe, Miho, Satoh, Yasuko, Hata, Junichi, Ishii, Nobuya, Aoki, Yuko

Volltext

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma von Okamoto, Aikou, Sehouli, Jalid, Yanaihara, Nozomu, Hirata, Yukihiro, Braicu, Ioana, Kim, Byoung-Gie, Takakura, Satoshi, Saito, Misato, Yanagida, Satoshi, Takenaka, Masataka, Yamaguchi, Noriko, Morikawa, Asuka, Tanabe, Hiroshi, Yamada, Kyosuke, Yoshihara, Kosuke, Enomoto, Takayuki, Itamochi, Hiroaki, Kigawa, Junzo, Matsumura, Noriomi, Konishi, Ikuo, Aida, Satoshi, Aoki, Yuko, Ishii, Nobuya, Ochiai, Kazunori, Akiyama, Tetsu, Urashima, Mitsuyoshi

Volltext

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer von Ono, Naomi, Yamazaki, Toshikazu, Tsukaguchi, Toshiyuki, Fujii, Toshihiko, Sakata, Kiyoaki, Suda, Atsushi, Tsukuda, Takuo, Mio, Toshiyuki, Ishii, Nobuya, Kondoh, Osamu, Aoki, Yuko

Volltext

A signature-based method for indexing cell cycle phase distribution from microarray profiles von Mizuno, Hideaki, Nakanishi, Yoshito, Ishii, Nobuya, Sarai, Akinori, Kitada, Kunio

Volltext

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers von Ono, Naomi, Yamazaki, Toshikazu, Nakanishi, Yoshito, Fujii, Toshihiko, Sakata, Kiyoaki, Tachibana, Yukako, Suda, Atsushi, Hada, Kihito, Miura, Takaaki, Sato, Shigeo, Saitoh, Ryoichi, Nakano, Kohnosuke, Tsukuda, Takuo, Mio, Toshiyuki, Ishii, Nobuya, Kondoh, Osamu, Aoki, Yuko

Volltext

Synthesis and structure–activity relationships of novel benzofuran farnesyltransferase inhibitors von Asoh, Kohsuke, Kohchi, Masami, Hyoudoh, Ikumi, Ohtsuka, Tatsuo, Masubuchi, Miyako, Kawasaki, Kenichi, Ebiike, Hirosato, Shiratori, Yasuhiko, Fukami, Takaaki A., Kondoh, Osamu, Tsukaguchi, Toshiyuki, Ishii, Nobuya, Aoki, Yuko, Shimma, Nobuo, Sakaitani, Masahiro

Volltext

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker von LEE, Lucy, HUIFENG NIU, GOELZER, Petra, DE SCHEPPER, Stefanie, YOSHIMURA, Yashushi, BARRETT, Joanne, ISHIKAWA, Yuji, WEISSGERBER, Georges, PECK, Richard, RUEGER, Ruediger, IGAWA, Yuriko, DEUTSCH, Jonathan, ISHII, Nobuya, SONG MU, SAKAMOTO, Yuuichiro, BUSSE-REID, Rachel, GIMMI, Claude

Volltext

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor von Nakanishi, Yoshito, Akiyama, Nukinori, Tsukaguchi, Toshiyuki, Fujii, Toshihiko, Sakata, Kiyoaki, Sase, Hitoshi, Isobe, Takehito, Morikami, Kenji, Shindoh, Hidetoshi, Mio, Toshiyuki, Ebiike, Hirosato, Taka, Naoki, Aoki, Yuko, Ishii, Nobuya

Volltext

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations von Voss, Martin H, Hierro, Cinta, Heist, Rebecca S, Cleary, James M, Meric-Bernstam, Funda, Tabernero, Josep, Janku, Filip, Gandhi, Leena, Iafrate, A John, Borger, Darrell R, Ishii, Nobuya, Hu, Youyou, Kirpicheva, Yulia, Nicolas-Metral, Valerie, Pokorska-Bocci, Anna, Vaslin Chessex, Anne, Zanna, Claudio, Flaherty, Keith T, Baselga, Jose

Volltext

YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification von Hamanaka, Natsuki, Nakanishi, Yoshito, Mizuno, Takakazu, Horiguchi-Takei, Kana, Akiyama, Nukinori, Tanimura, Hiromi, Hasegawa, Masami, Satoh, Yasuko, Tachibana, Yukako, Fujii, Toshihiko, Sakata, Kiyoaki, Ogasawara, Kiyomoto, Ebiike, Hirosato, Koyano, Hiroshi, Sato, Haruhiko, Ishii, Nobuya, Mio, Toshiyuki

Volltext

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine von Nagarajah, James, Le, Mina, Knauf, Jeffrey A, Ferrandino, Giuseppe, Montero-Conde, Cristina, Pillarsetty, Nagavarakishore, Bolaender, Alexander, Irwin, Christopher, Krishnamoorthy, Gnana Prakasam, Saqcena, Mahesh, Larson, Steven M, Ho, Alan L, Seshan, Venkatraman, Ishii, Nobuya, Carrasco, Nancy, Rosen, Neal, Weber, Wolfgang A, Fagin, James A

Volltext

Progress of research and development of MAPK pathway inhibitors von Ishii, Nobuya

Volltext

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity von ISHII, Nobuya, HARADA, Naoki, AOKI, Toshihiro, SHIMMA, Nobuo, ARISAWA, Mikio, SOWA, Yoshihiro, POULIKAKOS, Poulikos I, ROSEN, Neal, AOKI, Yuko, SAKAI, Toshiyuki, JOSEPH, Eric W, OHARA, Kazuhiro, MIURA, Takaaki, SAKAMOTO, Hiroshi, MATSUDA, Yutaka, TOMII, Yasushi, TACHIBANA-KONDO, Yukako, LIKURA, Hitoshi

Volltext

Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer von Sase, Hitoshi, Nakanishi, Yoshito, Aida, Satoshi, Horiguchi-Takei, Kana, Akiyama, Nukinori, Fujii, Toshihiko, Sakata, Kiyoaki, Mio, Toshiyuki, Aoki, Masahiro, Ishii, Nobuya

Volltext